<DOC>
	<DOCNO>NCT00960960</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study ass safety , tolerability , pharmacokinetics oral ( PO ) pictilisib administer letrozole intravenous ( IV ) paclitaxel without IV bevacizumab IV trastuzumab participant locally recurrent metastatic breast cancer . The study consist three part . Part 1 ( pictilisib administer 21+7 schedule along paclitaxel and/or bevacizumab ) , Part 2 ( pictilisib administer 5+2 schedule along paclitaxel and/or bevacizumab trastuzumab ) Part 3 ( pictilisib administer combination letrozole ) . Part 1 Part 2 consist two stage ; dose escalation stage cohort-expansion stage .</brief_summary>
	<brief_title>A Study PI3-Kinase Inhibitor GDC-0941 Combination With Paclitaxel , With Without Bevacizumab Trastuzumab , With Letrozole , Participants With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed adenocarcinoma breast locally recurrent metastatic disease Adequate organ bone marrow function assess laboratory test Evaluable disease disease measurable per RECIST Agreement use effective form contraception duration study History malabsorption syndrome condition would interfere enteral absorption Any condition require fulldose anticoagulant , warfarin , heparin , thrombolytic agent Prior anticancer therapy ( e.g. , chemotherapy , biologic therapy , radiotherapy , hormonal therapy ) within 4 week 5 halflives ( whichever short ) first dose study treatment Uncontrolled current illness Active small large intestine inflammation ( Crohn 's disease ulcerative colitis ) Clinically significant history liver disease , include cirrhosis , current alcohol abuse , current know active infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus Known HIV infection New York Heart Association ( NYHA ) Class II great congestive heart failure Active ventricular arrhythmia require medication Pregnancy , lactation , breastfeed Known significant hypersensitivity study drug excipients History arterial thromboembolic disease within 6 month first study treatment No two prior chemotherapy regimens metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MBC</keyword>
	<keyword>PI3K</keyword>
	<keyword>Avastin</keyword>
	<keyword>Herceptin</keyword>
</DOC>